



● Bilcare expands its clinical supplies manufacturing, storage and distribution facilities in India.

● Bilcare expands into Pre-clinical and Early Stage Development Capabilities in the US.

● Bilcare introduces a unique In-Sourcing Clinical Supplies Services for global pharma.

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, a unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

INDIA : USA : SINGAPORE : GERMANY : BRAZIL : CHINA : UK

Bilcare Limited

Regd. Office : 1028, Shirol, Pune 410 505.

Unaudited Financial Results for the quarter and nine months ended 31st December, 2008

(Rs. in Crores)

Sr. No.	Particulars	Standalone					Consolidated				
		Quarter Ended		Nine Months Ended		Year Ended 31st Mar. 2008	Quarter Ended		Nine Months Ended		Year Ended 31st Mar. 2008
		31st Dec. 2008	31st Dec. 2007	31st Dec. 2008	31st Dec. 2007		31st Dec. 2008	31st Dec. 2007	31st Dec. 2008	31st Dec. 2007	
		(Unaudited)		(Unaudited)		(Audited)	(Unaudited)		(Unaudited)		(Audited)
1.	a. Net Sales/Income from Operations	117.10	104.12	349.47	294.95	406.35	210.67	149.29	609.21	417.91	650.68
	b. Other Operating Income	4.18	3.32	(0.15)	8.47	15.77	5.02	3.43	1.68	9.39	19.24
2.	Expenditure										
	a. (Increase)/Decrease in Stock in Trade and Work in progress	(2.94)	1.86	(6.54)	(11.19)	(8.06)	(5.48)	1.96	(9.56)	(11.37)	(6.41)
	b. Consumption of Raw Materials	75.82	60.77	220.99	187.02	247.57	124.76	80.00	343.12	242.16	361.50
	c. Purchase of traded goods	---	---	---	---	---	---	---	---	---	---
	d. Employees Cost	5.15	4.02	14.81	11.71	15.64	22.78	15.42	59.29	44.07	60.55
	e. Depreciation	4.81	3.72	13.49	10.82	15.71	8.80	5.45	24.35	15.25	24.16
	f. Other Expenditure	8.89	9.14	26.57	26.37	38.29	27.63	14.78	87.19	43.82	91.57
	g. Total	91.73	79.51	269.32	224.73	309.15	178.50	117.61	504.39	333.93	531.37
3.	Profit from Operations before Other Income, Interest and Exceptional Items (1 - 2)	29.55	27.93	80.00	78.69	112.97	37.19	35.11	106.50	93.37	138.55
4.	Other Income	---	---	---	---	---	---	---	---	---	---
5.	Profit before Interest and Exceptional Items (3 + 4)	29.55	27.93	80.00	78.69	112.97	37.19	35.11	106.50	93.37	138.55
6.	Interest	5.26	2.80	14.20	8.29	11.44	10.09	3.08	28.38	9.17	14.27
7.	Profit after Interest but before Exceptional Items (5 - 6)	24.29	25.13	65.80	70.40	101.53	27.10	32.03	78.12	84.20	124.28
8.	Exceptional Items	---	---	---	---	---	---	---	---	---	---
9.	Profit from Ordinary Activities before Tax (7 + 8)	24.29	25.13	65.80	70.40	101.53	27.10	32.03	78.12	84.20	124.28
10.	Tax Expense	8.26	8.54	22.37	23.93	39.84	8.66	9.41	23.98	25.98	42.73
11.	Net Profit from Ordinary Activities after Tax (9 - 10)	16.03	16.59	43.43	46.47	61.69	18.44	22.62	54.14	58.22	81.55
12.	Extraordinary Items	---	---	---	---	---	---	---	---	---	---
13.	Net Profit for the period (11 - 12)	16.03	16.59	43.43	46.47	61.69	18.44	22.62	54.14	58.22	81.55
14.	Paid-up Equity Share Capital (face value Rs.10/- each)	17.21	16.45	17.21	16.45	16.45					
15.	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	---	---	---	---	346.79					372.39
16.	Earnings Per Share (EPS) (Rs.) after Extraordinary items for the period and for the previous year										
	- Basic	9.31	10.08	25.24	28.24	37.49					
	- Diluted	8.35	8.64	22.63	24.21	32.14					
17.	Public Shareholding										
	- No. of Shares	9,176,791	9,126,791	9,176,791	9,126,791	9,176,791					
	- Percentage of Shareholding	53.33%	55.47%	53.33%	55.47%	55.78%					

Notes :

1. The Company's main business segment is pharma packaging research solutions.
2. The Company had received 1 investor complaint during the quarter, which was redressed and there was no investor complaint pending for redressal. at the commencement and at the end of the quarter.
3. The Board of Directors has decided to delist Equity Shares of the Company from Pune Stock Exchange Limited and Ahmedabad Stock Exchange Limited, subject to required approvals.
4. In compliance with Schedule VI of the Companies Act 1956, and on the basis of legal advice received by the Company, fluctuations in foreign exchange rates related to borrowings in foreign currency and foreign currency convertible bonds (FCCBs) for acquisition of fixed assets are adjusted, during the current quarter, in carrying costs of fixed assets w.e.f. 1st April, 2008.
5. The previous year's figures have been regrouped / readjusted wherever necessary.
6. The above unaudited Financial Results were approved by the Board of Directors of the Company at its meeting held on 30th January, 2009.

For Bilcare Limited

Mohan H. Bhandari  
Managing Director

Pune : 30th January, 2009